TD Securities lowered their price target on shares of Barrick Gold Corporation (NYSE:ABX) from C$19.00 to C$16.00 in a research note issued on Tuesday. The firm currently has a “hold” rating on the stock. Barrick Gold Corporation (NYSE:ABX) in last trading activity fell -0.44% to close at $13.62. Company weekly performance is -0.37% while its quarterly performance stands at -27.13%. Barrick Gold Corporation (NYSE:ABX) is -35.99% away from its 52 week high. Orexigen Therapeutics Inc.'s (NASDAQ:OREX) recently approved prescription weight loss drug Contrave is now available across the United States. Orexigen has licensed North American Contrave rights to Takeda Pharmaceuticals. In Europe and throughout the rest of the world outside of North America, Orexigen owns Contrave rights. On last trading day Orexigen Therapeutics, Inc. (NASDAQ:OREX) advanced 11.08% to close at $4.51. Its volatility for the week is 10.82% while volatility for the month is 7.50%. OREX's sales growth for past 5 years was 102.40% and its EPS growth for past 5 years was 21.90%. Orexigen Therapeutics, Inc. (NASDAQ:OREX) monthly performance is 0.00%. Insulet Corporation (NASDAQ:PODD), the leader intubeless insulin pump technology with its OmniPod® Insulin Management System, plans to release its financial results for the third quarter of 2014 on November 5, 2014 after the close of the financial markets. On last trading day Insulet Corporation (NASDAQ:PODD) advanced 3.07% to close at $38.58. Its volatility for the week is 3.55% while volatility for the month is 3.98%. PODD's sales growth for past 5 years was 46.90% and its EPS growth for past 5 years was 24.70%. Insulet Corporation (NASDAQ:PODD) monthly performance is 5.35%. The Indian government and British telecom major Vodafone Group Plc (ADR) (NASDAQ:VOD) have extended the deadline to mutually find a third arbitrator to help resolve their Rs 20,000-crore tax dispute by a month after the October 17 deadline passed without an agreement. Vodafone Group Plc (ADR) (NASDAQ:VOD) institutional ownership stands at 11.60%. In last trading activity company's stock closed at $31.27. On October 6, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) received a $40 million milestone payment from its worldwide collaboration partner, Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP), upon the US Food and Drug Administration's approval last week of RELISTOR® Subcutaneous Injection for opioid-induced constipation in patients with chronic non-cancer pain. On Tuesday shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) closed at $4.70. Company's sales growth for last 5 years was -34.90% and EPS growth for next 5 years is recorded as 25.00%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
